Nano-X Imaging

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Neve Ilan, Israel.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Nano-X Imaging reports progress in regulatory clearances and strategic partnerships

Nano-X Imaging showcased progress in regulatory clearances, commercialization efforts, strategic partnerships, and operational optimization during the Q4 2022 Earnings Call.
Despite challenges in regulatory compliance, expenses management, and market competition, the company's strengths in innovation, partnerships, and financial resilience position it well for future growth.
Opportunities for Nano-X Imaging include global expansion, technological advancements, cost efficiencies, and leveraging market demand for imaging solutions.
Overall, Nano-X Imaging's performance in Q4 2022 reflects a strategic focus on growth, innovation, and market expansion in the medical imaging industry.

Nano-X Imaging reports improved Q1 performance and expands global reach

Nano-X Imaging's Q1 2023 performance showed improvement with a reported net loss of $11.8 million and revenue of $2.4 million. The company is focusing on deploying Nanox.ARC globally, strengthening manufacturing capabilities, and expanding market reach through strategic partnerships. Challenges include managing expenses and driving revenue growth to achieve profitability.

Nanox Imaging reports Q2 results, eyes U.S. market growth

Nanox Imaging's Q2 2023 performance reflects investment in growth initiatives, with a focus on market expansion and product deployment.
The company faces financial challenges, including a significant net loss and accrued expenses related to an SEC investigation, necessitating prudent financial management.
Strategic strengths in the U.S. market entry, global commercialization efforts, and strong cash position position Nanox Imaging for future growth and market success.
Opportunities lie in upcoming Investor Day, FDA clearance for Nanox.ARC, and expansion in Africa, offering avenues for revenue growth and market leadership.

Nanox Imaging reports Q3 revenue growth and strategic advancements

Nanox Imaging's Q3 2023 performance showed revenue growth and strategic advancements. While facing financial challenges and potential execution hurdles, the company's focus on expansion and partnerships positions it for future growth.

Nanox Imaging reports Q4 loss, eyes global expansion and AI

Nanox Imaging's Q4 2023 performance showed a mix of revenue growth and strategic investments in technology and market expansion.
The company's strengths lie in its progress with regulatory clearances, commercialization efforts, and success in AI applications.
Challenges include slow AI adoption, implementation hurdles, and the need to overcome barriers to data sharing and transparency.
Opportunities exist in expanding HealthCCS usage, global market presence, and addressing AI adoption challenges for revenue growth.

Nanox Imaging reports Q1 loss, eyes global expansion and AI growth

Nanox Imaging's Q1 2024 performance reflects revenue generation from AI solutions and system sales amid challenges in gross profit margins and a notable net loss.
The company's strategic strengths in partnerships, product launches, and global expansions position it well for future growth and market competitiveness.
While facing challenges in cost management and profitability, Nanox Imaging holds opportunities in expanded indications, market expansions, and AI solutions deployment.

Nano-X Imaging reports Q2 losses, eyes growth through FDA clearances

Nano-X Imaging (NNOX) showcased progress in commercial and clinical fronts but faces challenges in narrowing losses and optimizing operations.
Strategic collaborations, FDA clearances, and global deployment offer opportunities for growth and market expansion.
The focus on transformative imaging solutions and commercial infrastructure acceleration underlines NNOX's commitment to innovation and market leadership.

Nanox Imaging reports mixed Q3 results amidst growth opportunities

Nanox Imaging reported mixed financial results with revenue of $3.0 million and a gross loss of $2.8 million, while achieving record revenue from USARAD business.
The company showcased strengths in technology deployment, partnerships, and clinical trials, but faces challenges in regulatory clearances and financial performance.
Opportunities exist in market expansion, revenue growth, and operational efficiency improvements to drive future success and profitability.
With a strong focus on innovation, partnerships, and market expansion, Nanox is poised for growth but needs to address regulatory hurdles and financial performance.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Nano-X Imaging Ltd. is engaged in the development of medical imaging systems. Its product Nanox System consists of hardware Nanox.ARC and software Nanox.CLOUD that provides image repository, radiologist matching, online and offline diagnostics review and annotation, connectivity to diagnostic assistive artificial intelligence systems, billing, and reporting. The firm operates through the following segments: Nanox.Arc, AI Solutions, and Radiology Services. The company was founded by Ran Poliakine and Hitoshi Masuya in 2011 and is headquartered in Petach Tikva, Israel.

NEVE ILAN, Israel--(BUSINESS WIRE)--NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has filed its annual report on Form 20-F for the fiscal year ended December 31, 2021 with the U.S. Securities and Exchange Commission (“SEC”) on May 2, 2022. The annual report on Form 20-F, which contains the Company's audited consolidated financial statements, can be accessed on the SEC's website at www.sec.gov and on the Com

NANO-X IMAGING LTD Files 2021 Annual Report on Form 20-F

NEVE ILAN, Israel--(BUSINESS WIRE)--NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its deep-learning medical imaging analytics subsidiary, Nanox.AI, received FDA 510(k) clearance for HealthOST device, an AI software that provides qualitative and quantitative analysis of the spine from CT to support clinicians in the evaluation and assessment of musculoskeletal disease. Measurements of vertebral fractures and lo

Nanox Announces FDA Clearance for HealthOST Device, an AI Software Measuring Vertebral Compression Fractures and Low Bone Density, Which are Often Associated with Osteoporosis

The company is a tangible step closer to realizing its ultimate vision -- but it's still a long road ahead.

Why Nanox Stock Continued Jumping Higher Today

NEVE ILAN, Israel & YONGIN, South Korea--(BUSINESS WIRE)--NANO-X IMAGING LTD (“Nanox” or the “Company,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that it has opened its new semiconductor chip fabrication plant in South Korea. The facility is operational, opened on schedule, and will be the main production site of Nanox micro-electro-mechanical systems (“MEMs”) known as Nanox.SOURCE, a chip that produces the digital X-ray source for the Company's Nanox.ARC

Nanox Opens South Korean Fabrication Plant to Produce Semiconductor Chips for Novel Digital Nanox.ARC 3D X-ray System

The company reports its first quarter as a post-revenue business.

Why Nano-X Imaging Zoomed 15% Higher Today

Nano-X Imaging Ltd. (NNOX) CEO Erez Meltzer on Q4 2021 Results - Earnings Call Transcript

NEVE ILAN, Israel--(BUSINESS WIRE)--Nanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update

Nanox Announces Fourth Quarter 2021 Financial Results and Provides Business Update

Nano-X stock has been incredibly volatile. Is now a good time to buy?

Is This Revolutionary X-Ray Stock Grossly Undervalued?

NEVE ILAN, Israel--(BUSINESS WIRE)--Nanox to Report Fourth Quarter and Full Year 2021 Results on March 31, 2022

Nanox to Report Fourth Quarter and Full Year 2021 Results on March 31, 2022

NEVE ILAN, Israel--(BUSINESS WIRE)--Nanox to Present at Two Upcoming Investor Conferences in March 2022

Nanox to Present at Two Upcoming Investor Conferences in March 2022

NEVE ILAN, Israel--(BUSINESS WIRE)--NANO-X IMAGING LTD ("Nanox" or the "Company," Nasdaq: NNOX), an innovative medical imaging technology company, and its deep-learning medical imaging analytics subsidiary, Nanox.AI, today announced that the American Medical Association (AMA) has issued a new Category III Current Procedural Terminology (CPT) code for quantitative CT tissue characterization, enabling potentially broader use of Nanox.AI's HealthCCSng, an FDA-cleared AI-enabled cardiac imaging sol

Nanox Announces Issuance of American Medical Association New Category III CPT® Code for Its Coronary Artery Calcium Population Health Solution

This isn't the FDA clearance investors were looking for.

Why Nanox Stock Lost Almost 30% in December

NEVE ILAN, Israel--(BUSINESS WIRE)--NANO-X IMAGING LTD. (“Nanox,” Nasdaq: NNOX), an innovative medical imaging technology company, today announced that its wholly-owned subsidiary, USARAD Holdings, Inc., one of the world's leading teleradiology providers, has been re-certified with The Joint Commission's Gold Seal of Approval. The Joint Commission is the leading accrediting organization in the United States that certifies more than 22,000 health care organizations and programs based on the high

USARAD, a Nanox Company, Achieves the Joint Commission Re-Certification

NEW YORK, Dec. 6, 2021 /PRNewswire/ -- The following statement is being issued by Levi & Korsinsky, LLP: To: All persons or entities who purchased or otherwise acquired securities of Nano-X Imaging Ltd. ("Nano-X") (NASDAQ: NNOX)  between June 17, 2021 and August 18, 2021.

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Nano-X Imaging Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline TODAY - NNOX

New York, New York--(Newsfile Corp. - December 6, 2021) - WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between June 17, 2021 and August 18, 2021, inclusive (the "Class Period"), of the important December 6, 2021 lead plaintiff deadline.SO WHAT: If you purchased Nanox securities during the Class Period you may be entitled to compensation without payment of any out of pocket...

NNOX Final Deadline Today: Rosen, Leading Trial Attorneys, Encourages Nano-X Imaging Ltd. Investors with Losses to Secure Counsel Before Important December 6 Deadline in Securities Class Action - NNOX

San Francisco, California--(Newsfile Corp. - December 6, 2021) - Hagens Berman urges Nano-X Imaging Ltd. (NASDAQ: NNOX) investors with significant losses to submit your losses now. Class Period: June 17, 2021 - Aug. 18, 2021Lead Plaintiff Deadline: Dec. 6, 2021Visit: www.hbsslaw.com/investor-fraud/NNOXContact An Attorney Now: NNOX@hbsslaw.com844-916-0895Nano-X Imaging Ltd. (NNOX) Securities Fraud Class Action: Nano-X, a digital X-ray company, is developing the "Nanox.ARC," an imaging system that uses a purportedly novel X-ray source

HAGENS BERMAN, NATIONAL TRIAL ATTORNEYS, Alerts Nano-X Imaging (NNOX) Investors to Today's Lead Plaintiff Deadline, Investors with Significant Losses Should Contact Firm's Attorneys

New York, New York--(Newsfile Corp. - December 5, 2021) - The following statement is being issued by Levi & Korsinsky, LLP:To: All persons or entities who purchased or otherwise acquired securities of Nano-X Imaging Ltd. ("Nano-X") (NASDAQ: NNOX) between June 17, 2021 and August 18, 2021. You are hereby notified that a securities class action lawsuit has been commenced in the United States District Court for the Eastern District of New York. To get more...

SHAREHOLDER ALERT: Levi & Korsinsky, LLP Notifies Shareholders of Nano-X Imaging Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 6, 2021 - NNOX

NEW YORK--(BUSINESS WIRE)-- #NNOX--WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between June 17, 2021 and August 18, 2021, inclusive (the “Class Period”), of the important December 6, 2021 lead plaintiff deadline. SO WHAT: If you purchased Nano-X securities during the Class Period you may be entitled to compensation without payment of any out of pocket fees or costs through a contingency fee arrangement. WHAT TO DO NE

NNOX FINAL DEADLINE MONDAY: ROSEN, GLOBAL INVESTOR COUNSEL, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important December 6 Deadline in Securities Class Action – NNOX

New York, New York--(Newsfile Corp. - December 3, 2021) - The Klein Law Firm announces that a class action complaint has been filed on behalf of shareholders of Nano-X Imaging Ltd. (NASDAQ: NNOX) alleging that the Company violated federal securities laws.Class Period: June 17, 2021 to August 18, 2021Lead Plaintiff Deadline: December 6, 2021No obligation or cost to you.Learn more about your recoverable losses in NNOX:https://www.kleinstocklaw.com/pslra-1/nano-x-imaging-ltd-loss-submission-form-2?id=21904&from=5

NNOX ALERT: The Klein Law Firm Announces a Lead Plaintiff Deadline of December 6, 2021 in the Class Action Filed on Behalf of Nano-X Imaging Ltd. Limited Shareholders

NEW YORK, Dec. 3, 2021 /PRNewswire/ -- WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Nano-X Imaging Ltd. (NASDAQ: NNOX) between June 17, 2021 and August 18, 2021, inclusive (the "Class Period"), of the important December 6, 2021 lead plaintiff deadline.

NNOX FINAL DEADLINE MONDAY: ROSEN, A LONGSTANDING AND TRUSTED FIRM, Encourages Nano-X Imaging Ltd. Investors to Secure Counsel Before Important December 6 Deadline in Securities Class Action - NNOX

Los Angeles, California--(Newsfile Corp. - December 3, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nano-X Imaging Ltd. ("Nanox" or "the Company") (NASDAQ: NNOX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 17, 2021 and August 18, 2021, inclusive...

DEADLINE MONDAY ALERT: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Nano-X Imaging Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

New York, New York--(Newsfile Corp. - December 2, 2021) -  The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Nano-X Imaging Ltd. ("Nanox" or "the Company") (NASDAQ: NNOX) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.Investors who purchased the Company's securities between June 17, 2021 and August 18, 2021,...

MONDAY DEADLINE REMINDER: The Schall Law Firm Reminds Investors of a Class Action Lawsuit Against Nano-X Imaging Ltd. and Encourages Investors with Losses in Excess of $100,000 to Contact the Firm

LOS ANGELES--(BUSINESS WIRE)---- $NNOX #investors--The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nano-X Imaging Ltd. (NNOX)

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Nano-X Imaging Ltd.

SAN DIEGO, Dec. 2, 2021 /PRNewswire/ --  Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Nano-X Imaging Ltd. (NASDAQ: NNOX) securities between June 17, 2021 and August 18, 2021, inclusive (the "Class Period") have until this upcoming Monday, December 6, 2021 to seek appointment as lead plaintiff in McLaughlin v.

MONDAY DEADLINE: Nano-X Imaging Ltd. Investors with Substantial Losses Have Opportunity to Lead Class Action Lawsuit - NNOX

New York, New York--(Newsfile Corp. - December 1, 2021) - The securities litigation law firm of The Gross Law Firm issues the following notice on behalf of shareholders of Nano-X Imaging Ltd..Shareholders who purchased shares of NNOX during the class period listed are encouraged to contact the firm regarding possible Lead Plaintiff appointment. Appointment as Lead Plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/nano-x-imaging-ltd-loss-submission-form-2/?id=21846&from=5

SHAREHOLDER ALERT: The Gross Law Firm Notifies Shareholders of Nano-X Imaging Ltd. of a Class Action Lawsuit and a Lead Plaintiff Deadline of December 6, 2021 - (NNOX)

News for Nano-X Imaging Stock (NNOX)